Clinical Trials · NCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 336
- Start date
- Apr 2026
- Locations
- 1 site, China
- Primary endpoint
- To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.